Kendle Names Early Stage Executive

Pierre Geoffroy, M.D., CM, MSc, FCFP has been appointed vice president of Early Stage at Kendle. Dr. Geoffroy will oversee the development of early stage programs for customers worldwide, providing medical expertise and clinical insights for the development of early stage clinical trials. Dr. Geoffroy will be based at the company’s Early Stage unit in Toronto and will report to Kendle’s president and chief executive officer Stephen Cutler, Ph.D.

Dr. Geoffroy joins the company from Lambda Therapeutic Research, where he most recently served as chief medical officer, vice president and principal investigator. He also has served in senior clinical roles at multiple global biopharmaceutical companies, including Sanofi Pasteur, Wyeth Ayerst K.K., Wyeth Research Canada, Hoffmann La Roche and SmithKline Beecham.

“We are thrilled to welcome Dr. Geoffroy to Kendle,” said Dr. Cutler. ”He brings extensive expertise in early stage development to assist our customers in making strategic decisions related to the future of their compounds. We look forward to his leadership as we focus on positioning Kendle’s Early Stage operations for growth.”